Ipamorelin — 10mg | Selective GHS-R1a Pentapeptide

Ipamorelin is a synthetic pentapeptide selective ghrelin / growth hormone secretagogue receptor (GHS-R1a) agonist, originally developed by Novo Nordisk in the late 1990s as a research compound. The peptide consists of five amino acids with two non-natural residues (Aib at position 1, D-2-naphthylalanine at position 3) designed to enhance receptor selectivity and metabolic stability. Ipamorelin is studied as one of the most selective GHS-R1a agonists characterized in research literature, reportedly stimulating endogenous growth hormone release without significant effects on cortisol, prolactin, ACTH, or aldosterone secretion — a selectivity profile that distinguishes it from earlier-generation GH secretagogues such as GHRP-6 and hexarelin. The compound is investigated in preclinical research for somatotropic axis pharmacology, GH release dynamics, and receptor selectivity studies, and is frequently paired with GHRH analogs (CJC-1295 No DAC, tesamorelin, sermorelin) in combined-pathway research protocols.

Benefits (Research Focus)

• Selective GHS-R1a agonism — studied as a highly selective ghrelin receptor agonist with minimal off-target receptor activity

• GH release research — investigated for endogenous growth hormone release from pituitary somatotropes

• Hormone selectivity — explored for reported minimal effects on cortisol, prolactin, ACTH, and aldosterone vs. other GH secretagogues

• IGF-1 axis signaling — examined for downstream hepatic IGF-1 production and somatotropic endpoints

• Combination pharmacology — researched alongside GHRH analogs (CJC-1295, tesamorelin) for paired pathway studies

What Researchers Look At

• GHS-R1a receptor binding affinity and selectivity profiles

• Plasma GH and IGF-1 dynamics following ipamorelin administration

• Cortisol, prolactin, and ACTH response panels (selectivity markers)

• Comparative pharmacology versus GHRP-6, hexarelin, MK-677, and other GH secretagogues

• Combined GHRH + GHS-R receptor pharmacology in paired-peptide research protocols

Quick Specs

• Form: Lyophilized white powder

• Net Peptide Content: 10 mg per vial

• Quantity: 1 vial

• Appearance: White to off-white lyophilizate

• Reconstitution: Bacteriostatic or sterile water (added by the end researcher)

• Purity: ≥99% by HPLC

• Identity: MS-verified (per COA)

• Storage: Protect from light

Identity Basics

• Compound: Ipamorelin

• Synonyms: NNC 26-0161; NNC26-0161

• Class: Selective ghrelin / GHS-R1a agonist; pentapeptide; growth hormone secretagogue

• Sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH₂ (5 amino acids; Aib = α-aminoisobutyric acid; D-2-Nal = D-2-naphthylalanine)

• Formula / M.W.: C₃₈H₄₉N₉O₅, ~711.85 g/mol

• CAS: 170851-70-4

⚠️ Disclaimer

• This product is intended for laboratory research use only.
• Not for human or veterinary use.
• Not approved for diagnostic, therapeutic, or medical applications.
• Handle using appropriate laboratory safety procedures and personal protective equipment.

COA Verification Notice: Even if the vial label or product image states a certain concentration, always go by the COA for the true verified value. We reference the COA to determine the verified concentration and purity of each product, regardless of what the label or product image indicates.

Janoshik COA — Third-Party Testing

• Ipamorelin Batch COA — September 25, 2025

• Ipamorelin VPeptide Canada — March 24, 2026

• Ipamorelin VPeptide Canada — June 8, 2026